Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.83 - $3.02 $34,770 - $57,380
-19,000 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$2.88 - $4.3 $49,320 - $73,637
-17,125 Reduced 47.4%
19,000 $55,000
Q3 2021

Nov 15, 2021

SELL
$3.72 - $5.35 $132,699 - $190,845
-35,672 Reduced 49.68%
36,125 $153,000
Q2 2021

Aug 16, 2021

BUY
$3.83 - $5.98 $219,826 - $343,228
57,396 Added 398.56%
71,797 $380,000
Q1 2021

May 17, 2021

BUY
$3.33 - $8.76 $47,955 - $126,152
14,401 New
14,401 $67,000
Q1 2020

May 15, 2020

SELL
$2.9 - $6.16 $83,285 - $176,909
-28,719 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$5.61 - $8.57 $98,820 - $150,960
17,615 Added 158.64%
28,719 $173,000
Q3 2019

Nov 14, 2019

BUY
$7.56 - $15.44 $83,946 - $171,445
11,104 New
11,104 $84,000

Others Institutions Holding ZYNE

About Zynerba Pharmaceuticals, Inc.


  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.